ATE505472T1 - Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen - Google Patents

Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen

Info

Publication number
ATE505472T1
ATE505472T1 AT06777183T AT06777183T ATE505472T1 AT E505472 T1 ATE505472 T1 AT E505472T1 AT 06777183 T AT06777183 T AT 06777183T AT 06777183 T AT06777183 T AT 06777183T AT E505472 T1 ATE505472 T1 AT E505472T1
Authority
AT
Austria
Prior art keywords
treatment
pyridine derivatives
psychotic diseases
psychotic
diseases
Prior art date
Application number
AT06777183T
Other languages
English (en)
Inventor
Giuseppe Alvaro
Daniele Andreotti
Sandro Belvedere
Fabio Romano Di
Alessandro Falchi
Riccardo Giovannini
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE505472(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0518472A external-priority patent/GB0518472D0/en
Priority claimed from GB0611153A external-priority patent/GB0611153D0/en
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of ATE505472T1 publication Critical patent/ATE505472T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT06777183T 2005-09-09 2006-09-07 Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen ATE505472T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0518472A GB0518472D0 (en) 2005-09-09 2005-09-09 Novel compounds
GB0611153A GB0611153D0 (en) 2006-06-06 2006-06-06 Novel compounds
PCT/EP2006/008845 WO2007028654A1 (en) 2005-09-09 2006-09-07 Pyridine derivatives and their use in the treatment of psychotic disorders

Publications (1)

Publication Number Publication Date
ATE505472T1 true ATE505472T1 (de) 2011-04-15

Family

ID=37546936

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06777183T ATE505472T1 (de) 2005-09-09 2006-09-07 Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen

Country Status (28)

Country Link
US (3) US7683056B2 (de)
EP (2) EP1928886B1 (de)
JP (1) JP5121716B2 (de)
KR (1) KR101292348B1 (de)
CN (1) CN101305011B (de)
AR (1) AR058805A1 (de)
AT (1) ATE505472T1 (de)
AU (1) AU2006289281B2 (de)
BR (1) BRPI0615787B8 (de)
CA (1) CA2621564C (de)
CR (1) CR9847A (de)
CY (1) CY1111907T1 (de)
DE (1) DE602006021323D1 (de)
DK (1) DK1928886T3 (de)
EA (1) EA013909B1 (de)
HR (1) HRP20110457T1 (de)
IL (1) IL189578A (de)
JO (1) JO2722B1 (de)
MA (1) MA29780B1 (de)
MY (1) MY145713A (de)
NO (1) NO340921B1 (de)
NZ (1) NZ565983A (de)
PE (1) PE20070614A1 (de)
PL (1) PL1928886T3 (de)
PT (1) PT1928886E (de)
SI (1) SI1928886T1 (de)
TW (1) TWI378101B (de)
WO (1) WO2007028654A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039123A2 (en) * 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
EP1943216B1 (de) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamidderivate als natriumkanalmodulatoren
ES2778846T3 (es) 2005-11-08 2020-08-12 Vertex Pharma Moduladores heterocíclicos de transportadores de casete de unión a ATP
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物
WO2008135826A2 (en) 2007-05-03 2008-11-13 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
CN102863432B (zh) 2007-05-09 2016-09-07 沃泰克斯药物股份有限公司 Cftr调节剂
WO2009076142A2 (en) 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
KR20150063170A (ko) 2007-12-07 2015-06-08 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
PL2098526T3 (pl) * 2008-02-22 2014-06-30 Neurotune Ag Bicykliczne związki zawierające azot aktywne w stanach przewlekłego bólu
CN106432213A (zh) 2008-02-28 2017-02-22 沃泰克斯药物股份有限公司 作为cftr调节剂的杂芳基衍生物
FR2928150A1 (fr) 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
WO2009119528A1 (ja) * 2008-03-24 2009-10-01 武田薬品工業株式会社 複素環化合物
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
EP2145891A1 (de) 2008-07-09 2010-01-20 Vetoquinol S.A. 9-substierte 5-Carboxy-Oxadiazin-Chinolon-Derivate, ihre Herstellung und ihre Anwendung als antibakterielle Mittel
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
US20110034469A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Heterocyclic Compound
JP2013503134A (ja) * 2009-08-27 2013-01-31 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 無水形態のピリジン誘導体
WO2011054773A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Novel lactam compounds
BR112012026255A2 (pt) 2010-04-07 2017-03-14 Vertex Pharma composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
EP2590953B1 (de) 2010-07-09 2014-10-29 Convergence Pharmaceuticals Limited Tetrazolverbindungen als calciumkanalblocker
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
CN102617503B (zh) * 2011-03-03 2014-05-07 上海常丰生物医药科技有限公司 (s)-3-吗啉基羧酸的合成方法
TW201321384A (zh) 2011-09-29 2013-06-01 Abbvie Inc 作為鈣通道阻斷劑之經取代之八氫吡咯并［１，２－ａ］吡□磺醯胺
US8669255B2 (en) 2011-09-29 2014-03-11 Abbvie Inc. Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers
DK2806859T3 (da) 2012-01-25 2019-08-05 Vertex Pharma Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
US9029361B2 (en) 2012-12-12 2015-05-12 Abbvie Inc. Agents for treating pain and uses thereof
CA2930008A1 (en) 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
DK3068392T5 (da) 2013-11-12 2021-09-20 Vertex Pharma Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
WO2016021562A1 (ja) * 2014-08-06 2016-02-11 キッセイ薬品工業株式会社 シアノチオフェン誘導体
WO2016081556A1 (en) 2014-11-18 2016-05-26 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
JP6902682B2 (ja) * 2015-05-18 2021-07-14 カンディー セラピューティクス リミテッド 性ホルモン依存性疾患を治療するためのｎｋ−１／ｎｋ−３受容体デュアルアンタゴニスト
JP2020536870A (ja) 2017-10-05 2020-12-17 バイオジェン インコーポレイテッド アルファカルボキサミドピロリジン誘導体の調製方法
EA202092131A1 (ru) 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
AU2020381762B2 (en) 2019-11-15 2026-01-22 KaNDy Therapeutics Limited New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of NT-814
KR102682775B1 (ko) * 2020-06-26 2024-07-08 홀로스메딕 주식회사 신규한 화합물의 제조방법
WO2021261969A1 (ko) * 2020-06-26 2021-12-30 홀로스메딕 주식회사 신규한 화합물의 제조방법
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
EP4319735A4 (de) * 2021-04-05 2025-05-07 The Board of Trustees of the Leland Stanford Junior University Enantiomerenselektive wirkung auf die neurotransmission
EP4431512A1 (de) 2023-03-16 2024-09-18 Bayer Consumer Care AG Neue duale nk-1/nk-3-rezeptorantagonisten
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
WO2025242584A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag A stable soft gelatin capsule formulation for elinzanetant
WO2025261856A1 (en) 2024-06-18 2025-12-26 Bayer Consumer Care Ag Improved process for producing an elinzanetant precursor
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921855A (en) 1987-06-22 1990-05-01 Fujisawa Pharmaceutical Co., Ltd. New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same
US5166203A (en) 1990-08-30 1992-11-24 Kanebo, Ltd. Quinolinecarboxylic acid derivatives, antibacterial agent containing the same
SI1004583T1 (en) 1998-11-23 2004-12-31 Pfizer Products Inc. Process and hydantoin intermediates for the synthesis of growth hormone secretagogues
DE60045564D1 (de) 1999-02-24 2011-03-03 Hoffmann La Roche 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
DOP2000000107A (es) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
JP4490421B2 (ja) 2003-07-03 2010-06-23 エフ．ホフマン−ラ ロシュ アーゲー 統合失調症を処置するデュアルｎｋ１／ｎｋ３アンタゴニスト

Also Published As

Publication number Publication date
MY145713A (en) 2012-03-30
PL1928886T3 (pl) 2011-09-30
US20110190276A1 (en) 2011-08-04
PT1928886E (pt) 2011-07-14
JP2009507801A (ja) 2009-02-26
US8097618B2 (en) 2012-01-17
EP1928886A1 (de) 2008-06-11
NO340921B1 (no) 2017-07-17
AU2006289281B2 (en) 2012-05-17
BRPI0615787B1 (pt) 2020-08-11
US7919491B2 (en) 2011-04-05
EA013909B1 (ru) 2010-08-30
US7683056B2 (en) 2010-03-23
HRP20110457T1 (hr) 2011-07-31
IL189578A0 (en) 2008-08-07
KR101292348B1 (ko) 2013-09-09
CN101305011B (zh) 2011-03-02
AR058805A1 (es) 2008-02-27
EA200800784A1 (ru) 2008-06-30
BRPI0615787B8 (pt) 2021-05-25
CN101305011A (zh) 2008-11-12
KR20080046232A (ko) 2008-05-26
CA2621564C (en) 2014-06-03
AU2006289281A1 (en) 2007-03-15
CR9847A (es) 2008-07-29
IL189578A (en) 2015-10-29
US20100152175A1 (en) 2010-06-17
TW200804401A (en) 2008-01-16
PE20070614A1 (es) 2007-08-02
DK1928886T3 (da) 2011-07-11
DE602006021323D1 (de) 2011-05-26
US20080269208A1 (en) 2008-10-30
MA29780B1 (fr) 2008-09-01
WO2007028654A1 (en) 2007-03-15
CY1111907T1 (el) 2015-11-04
SI1928886T1 (sl) 2011-08-31
CA2621564A1 (en) 2007-03-15
BRPI0615787A2 (pt) 2009-06-16
JO2722B1 (en) 2013-09-15
EP1928886B1 (de) 2011-04-13
EP2336136A1 (de) 2011-06-22
JP5121716B2 (ja) 2013-01-16
TWI378101B (en) 2012-12-01
NZ565983A (en) 2011-04-29
NO20081728L (no) 2008-04-07

Similar Documents

Publication Publication Date Title
ATE505472T1 (de) Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen
ATE448206T1 (de) Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen
ATE432924T1 (de) 3-aminoindazole derivate und ihre verwendung zur behandlung sgk-bedingten krankheiten
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE530553T1 (de) Zytotoxische mittel mit neuen tomamycin-derivaten und ihre therapeutische verwendung
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
IS8134A (is) Píperasínafleiður og notkun þeirra til að meðhöndla tauga- og geðsjúkdóma
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
NO20055588D0 (no) Pyrimidinderivater anvendelige for behandling av sykdommer mediert av CRTH2
DE602005016142D1 (de) 1-alkinyl-2-aryloxyalkylamide und ihre verwendung als fungizide
ATE475661T1 (de) Triazolopyridin-carboxamid-derivate sowie ihre herstellung und therapeutische verwendung
ATE430133T1 (de) N-hydroxyamid derivate und ihre verwendung
ATE489091T1 (de) Dha-ester und ihre verwendung bei der behandlung und der prävention von kardiovaskulären erkrankungen
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
DE502005003904D1 (de) Tetrahydrobenzo (d) azepin-2-on derivate und ihre verwendung zur behandlung von kardiovaskulären krankheiten
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
DE602004020486D1 (de) Pyridin-derivate und ihre verwendung als urotensin ii antagonisten
ATE459608T1 (de) Oxopiperidinderivate, ihre herstellung und therapeutische verwendung
ATE420081T1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
ATE448211T1 (de) 1,2,4-triazinderivate, ihre herstellung und ihre verwendung in der humantherapie
SI1831227T1 (sl) Nove heterociklične spojine uporabne za zdravljenje vnetnih in alergijskih motenj
ATE388145T1 (de) Imidazol-derivate und ihre verwendung in der behandlung von mglur5-rezeptor vermittelten krankheiten
ATE405565T1 (de) Herstellung von 6-substituierten pyridoindolon- derivaten und ihre therapeutische verwendung
ATE323091T1 (de) In 3-position heterocyclisch substituierte pyridoindolonderivate, ihre herstellung und ihre therapeutische verwendung
ITMI20061218A1 (it) Derivati pepticidi e loro attivita' terapeutica

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1928886

Country of ref document: EP